Document is current
Any future updates will be listed below
-
Authors
Ethridge, Lauren E.
Pedapati, Ernest V.
Schmitt, Lauren M.
Norris, Jordan E.
Auger, Emma
De Stefano, Lisa A.
Sweeney, John A.
Erickson, Craig A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (U54HD082008)
National Institutes of Health (U54HD104461)
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 11 September 2024
First Online: 3 October 2024
Declarations
:
: L.E.E. has received consulting fees or project funding from Ultragenyx, Tetra Therapeutics, Healx, Novartis, and Autifony Therapeutics. CAE and EVP are inventors on a patent(s) that focus on new treatment development in fragile X syndrome held by the Cincinnati Children’s Research Foundation (CCRF) and licensed out at the discretion of CCRF. CAE is a current consultant to Impel, Stalicla, and Scioto Bioscience. L.S., J.E., L.D. E.A. and J.S. declare no competing interests.
